Clearbridge BioMedics Joins CANCER-ID Consortium

Clearbridge BioMedics is the first Asian biotechnology company to join the CANCER-ID consortium for blood-based biomarker evaluation.

AsianScientist (Oct. 3, 2017) – Clearbridge BioMedics, a biotechnology company based in Singapore, has joined CANCER-ID, a public-private international consortium that aims to establish standard protocols for blood-based biomarkers.

Founded in 2015 and backed by the Innovative Medicines Initiative (IMI), CANCER-ID currently has 38 partners from 14 countries, including Clearbridge Biomedics. The company is the consortium’s first partner headquartered in Asia.

The CANCER-ID consortium brings together experts from academic medical centers and industry engaged in oncology research and patient care who are working to advance cancer treatment and therapy monitoring by using circulating tumor cells (CTCs) and tumor-related DNA (ctDNA) found in the blood. CANCER-ID supports a number of innovative research projects aimed at developing clinical utility in anticancer therapy and the tracking of treatment responses, through the identification of biomarkers in blood, specifically for lung and breast cancer.

Clearbridge BioMedics has developed the proprietary ClearCell® FX System, which is a label-free, enrichment and isolation platform that retrieves intact, live CTCs from a patient’s blood sample. The technology enables seamless processing of both CTCs and ctDNA from the same patient blood sample for subsequent analysis.

It is currently being used in cancer research and clinical trials to better understand the underlying biology of cancer, to gain new insights into the disease and improve patient management. The ClearCell® FX System has also been deployed at several academic consortium partners and hospitals for research projects under CANCER-ID.

“We believe that the use of liquid biopsy will play a critical role in advancing cancer diagnostics and personalized medicine. By participating in the CANCER-ID consortium, we aim to accelerate the adoption of CTC-based diagnostics in the clinic. This will ultimately lead to better patient management and improved outcomes for cancer patients,” said Dr. Michael Paumen, CEO of Clearbridge BioMedics.


Source: Clearbridge BioMedics; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist